Somaxon Could Seek Buyer For Silenor Sleep Aid, OTC Marketing Rights
This article was originally published in The Tan Sheet
Executive Summary
Somaxon reconsiders its options and might sell the sleep aid Silenor, despite a “clear path” to switch OTC, after the firm’s stock fell from $10.60 per share to 42 cents per share. Procter & Gamble would have first crack at exclusive OTC marketing rights if Somaxon sells Silenor.